News articles about Johnson & Johnson (NYSE:JNJ) have trended somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Johnson & Johnson earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.280794627598 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Sinuplasty Offers Help for Sinus-Related Sleep Apnea (prweb.com)
- The Right Time To Buy Johnson & Johnson (seekingalpha.com)
- How J&J Can Be A $150 Stock (finance.yahoo.com)
- J&J wins California lawsuit claiming asbestos in talc caused cancer (finance.yahoo.com)
- Gauging JNJ’s Recovery from the 3Q17 Hurricanes (finance.yahoo.com)
JNJ has been the topic of several research analyst reports. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 price target on the stock in a research report on Thursday, July 27th. Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Friday, August 4th. J P Morgan Chase & Co raised their price target on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Tuesday, August 15th. Finally, Cowen and Company set a $147.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, August 24th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $143.70.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the previous year, the company posted $1.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year. analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.43%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Earning Somewhat Favorable Media Coverage, Accern Reports” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://sportsperspectives.com/2017/11/19/johnson-johnson-jnj-earning-somewhat-favorable-media-coverage-accern-reports.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.